Details for Patent: 9,907,794
✉ Email this page to a colleague
Which drugs does patent 9,907,794 protect, and when does it expire?
Patent 9,907,794 protects LATUDA and is included in one NDA.
Protection for LATUDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-five patent family members in twenty-two countries.
Summary for Patent: 9,907,794
| Title: | Pharmaceutical composition |
| Abstract: | A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethyle- ne-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied. |
| Inventor(s): | Fujihara; Kazuyuki (Suzuka, JP) |
| Assignee: | SUMITOMO DAINIPPON PHARMA CO., LTD (Osaka, JP) |
| Application Number: | 14/733,204 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,907,794 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,907,794
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-003 | Dec 7, 2011 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-001 | Oct 28, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-005 | Jul 12, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-002 | Oct 28, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-004 | Apr 26, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,907,794
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2005-153508 | May 26, 2005 |
International Family Members for US Patent 9,907,794
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1884242 | ⤷ Sign Up | 92550 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1884242 | ⤷ Sign Up | C300690 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1884242 | ⤷ Sign Up | CA 2014 00049 | Denmark | ⤷ Sign Up |
| European Patent Office | 1884242 | ⤷ Sign Up | PA2014034 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1884242 | ⤷ Sign Up | C20140030 00118 | Estonia | ⤷ Sign Up |
| European Patent Office | 1884242 | ⤷ Sign Up | 1490057-5 | Sweden | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
